Principal Display Panel (20 mg Capsule)
Temodar
Product Images NDC 54868-5348
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Temodar (NDC 54868-5348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (5 mg Capsule)
Principal Display Panel (100 mg Capsule)
Principal Display Panel (250 mg Capsule)
Not available. The text seems to be a collection of random characters without any apparent meaning or coherence.*
Principal Display Panel (180 mg Capsule)
This text contains information about a medication called "Tehodar" which is a 186KG capsule distributed by Physicians Total Care. The medication has an NDC number of 54868-5986-0 and comes in a 14 capsule package. The lot number is 6000 and the expiration date is 61/60. There is also a code of "WG W SoERIG coomTion" and a number of "59208140000".*
Table 4: Dosing Modification Table (Temodar 01)
This seems to be a medical document with instructions on dosage and measurement for a therapy cycle. The starting dose is either 150 mgim?/d x 54 or 200 mg/m?/d x 5. Measurements need to be taken on Day 22 and Day 29 for ANG, platelets, and ANC. The decision on whether to postpone therapy or maintain the dose depends on the count of ANC and platelets on Day 22 and Day 29. If ANC is less than 1000/uL or platelets are less than 50,000/uL, then therapy should be postponed. If ANC is greater than 15004L and platelets are greater than 100,000/L, then it is okay to continue with the therapy. Otherwise, the dosage should be adjusted.*
Chemical Structure (Temodar 02)
Figure 1: Kaplan-meier Curves For Overall Survival (itt Population) (Temodar 03)
The text seems to be a statistical analysis of a medical study regarding Overall Survival in an ITT (Intent-to-Treat) Population. The HR (Hazard Ratio) is reported as 0.63 with a 95% CI (Confidence Interval) of 0.52-0.75, which suggests a statistically significant benefit in the group being studied. The analysis seems to have been conducted over a period of 24 months and the p-value is reported as less than 0.0001.*
Table (Temodar 04)
This appears to be a medical document with dosing instructions for a medication. The starting dose is either 150 mg, taken once a day for five days, or 200 mg taken once a day for five days. On day 22, ANC and platelets should be measured, and on day 20 of the next cycle, they should be measured again. If ANC is less than 1,000/uL or platelets are less than 50,000/uL, the dose should be postponed or reduced by 50% for the subsequent cycle. If ANC is between 1,000-1,499/uL or platelets are between 50,000-99,999/uL, the dose may be continued with caution. If ANC is 1,500/uL or greater and platelets are 100,000 or greater, the dose may be continued as normal.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
